OP01: In-depth characterization of host-genetics and gut microbiome unravels novel host-microbiome interactions in Inflammatory Bowel DiseaseECCO'19 Copenhagen 2019
1
OP02: The role of PTPN2 SNP in the pathogenesis of fibrosis in Crohn’s DiseaseECCO'19 Copenhagen 2019
1
OP07: Analysing intestinal organoids in a multi-omics, systems biology framework to investigate functional processes affected in Crohn’s disease due to autophagy impairmentECCO'19 Copenhagen 2019
1
OP10: Systems genomics of ulcerative colitis: combining GWAS and signalling networks for patient stratification and individualised drug targeting in ulcerative colitisECCO'19 Copenhagen 2019
1
OP11: Organoids derived from inflamed intestinal biopsies of patients with ulcerative colitis lose their inflammatory phenotype during ex vivo cultureECCO'19 Copenhagen 2019
1
OP12: Targeting inflammation in ulcerative colitis by inhibiting glucose uptakeECCO'19 Copenhagen 2019
1
OP13: Molecular response to ustekinumab in moderate-to-severe ulcerative colitis by serum protein and biopsy gene expression analysis: Results from the UNIFI phase 3 induction studyECCO'19 Copenhagen 2019
1
OP14: Improved endoscopic outcomes and mucosal healing of upadacitinib as an induction therapy in adults with moderately-to-severely active ulcerative colitis: data from the U-ACHIEVE studyECCO'19 Copenhagen 2019
1
OP16: A randomised, multicentre, double-blind, placebo-controlled study of a targeted release oral cyclosporine formulation in the treatment of mild to moderate ulcerative colitis: efficacy resultsECCO'19 Copenhagen 2019
1
OP17: A molecular measure of inflammation in IBD patients based on transcriptional profiles from 2495 intestinal biopsiesECCO'19 Copenhagen 2019
1
OP19: Corticosteroid response rectal gene signature and associated microbial variation in treatment naïve ulcerative colitisECCO'19 Copenhagen 2019
1
OP20: Mucosal microRNA profiles predict response to autologous stem-cell transplantation in Crohn’s Disease.ECCO'19 Copenhagen 2019
1
OP21: ABX464 is safe and efficacious in a proof of concept study in ulcerative colitis patientsECCO'19 Copenhagen 2019
1
OP23: CKD-506, a novel histone deacetylase (HDAC) 6 inhibitor, ameliorates colitis in various animal modelsECCO'19 Copenhagen 2019
1
OP24: Effectiveness and safety of ustekinumab 90 mg every four weeks in Crohn's diseaseECCO'19 Copenhagen 2019
1
OP25: Targeting endoscopic outcomes through combined pharmacokinetic and pharmacodynamic monitoring of infliximab therapy in patients with Crohn’s diseaseECCO'19 Copenhagen 2019
1
OP26: Long-term safety of vedolizumab in ulcerative colitis and Crohn’s disease: Final results from the GEMINI LTS studyECCO'19 Copenhagen 2019
1
OP29: ST2+/IL-33 responsive cells promote tumorigenesis in colitis-associated colorectal cancerECCO'19 Copenhagen 2019
1